Search

Don W Moss

from Waltham, MA
Age ~58
Get Report
Also known as:
Don William Moss, Moss Moss
Phone and address:
97 Maple St, Waltham, MA 02453
(781) 893-1773
Related to:
Rosalie Bugelholl, 87Joseph Lombardo, 60Dennis Bugelholl, 66
Connected to:
Aaron D Moss, 47Adina Moss, 44Adlai Moss, 40Ahmad R Moss, 42Aleshia B Moss, 38Alycia M Moss, 38Alyson Moss, 35Ana J Moss, 68Angela Moss, 41Annyana L Moss, 45

Don Moss Phones & Addresses

  • 97 Maple St, Waltham, MA 02453 (781) 893-1773
  • West Pittston, PA
  • 119 6Th Ave, Brunswick, MD 21716
  • Columbus, OH
  • Louisville, KY
  • W Jefferson, OH
  • New Market, MD

Resumes

Resumes

Don Moss Photo 1

Founder & Ceo At Global Green Energy Corp.

View page
Position:
Founder & CEO at Global Green Energy Corp.
Location:
Olympia, Washington
Industry:
Renewables & Environment
Work:
Global Green Energy Corp. - Olympia WA since Aug 2010
Founder & CEO
Cleantech Open 2012 - 2012
Semi-Finalist
Moss On Earth Farm Jul 2005 - Nov 2009
Retired
Skills:
Solar Energy
Renewable Energy
Strategic Planning
Business Strategy
Cleantech
Energy
Sustainability
Project Management
Entrepreneurship
Alternative Energy
Energy Efficiency
Interests:
Renewable Energy
Honor & Awards:
B Corporation Best of the Best for The Environment Award B Corporation Best of the Best for Overall Impact Award 2012 Zino Zenith Award for Best Investment Opportunity 2012 Zino Fund Finalist
Don Moss Photo 2

Don Moss

View page
Location:
Greater Boston Area
Industry:
Fishery
Don Moss Photo 3

At Donald Moss, M.d.

View page
Location:
United States

Business Records

Name / Title
Company / Classification
Phones & Addresses
Don Moss
President
Canadian Auto Glass
Automobile Repair - Windshield. Glass Shops. Automobile Detailing
2702 45 Ave, Vernon, BC V1T 3N4
(250) 558-4527

Publications

Us Patents

Detecting Complement Activation

View page
US Patent:
20120315266, Dec 13, 2012
Filed:
May 1, 2012
Appl. No.:
13/461709
Inventors:
Paul Olson - St. Louis MO, US
Don W. Moss - Louisville KY, US
Nicholas Staten - Kirkwood MO, US
Assignee:
KYPHA, INC. - St. Louis MO
International Classification:
G01N 33/566
A61P 29/00
A61P 31/00
A61P 27/02
A61P 25/00
A61P 13/12
A61K 39/395
A61P 9/00
US Classification:
4241301, 436501, 435 792, 435 71
Abstract:
Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided.

Lateral Flow Immunoassay For Complement Activation And Methods Of Use For Point-Of-Care Assessment Of Complement-Associated Disorders

View page
US Patent:
20120141457, Jun 7, 2012
Filed:
Nov 2, 2011
Appl. No.:
13/287432
Inventors:
Paul Olson - St. Louis MO, US
Don W. Moss - Louisville KY, US
Assignee:
Kypha, Inc. - St. Louis MO
International Classification:
A61K 39/395
G01N 33/566
A61P 31/00
A61P 29/00
A61P 11/00
A61P 9/00
A61P 27/02
A61P 25/00
A61P 15/00
A61P 13/12
A61K 38/12
A61P 43/00
US Classification:
4241301, 514 211, 436501, 435 71
Abstract:
A method for treating an individual at risk for a complement-associated disorder is provided, including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d). Lateral flow immunoassays and a method of monitoring an individual suffering from a complement-associated disorder are also provided herein.

Detecting Complement Activation

View page
US Patent:
20160084833, Mar 24, 2016
Filed:
Sep 4, 2015
Appl. No.:
14/845785
Inventors:
- St. Louis MO, US
Don W. Moss - Louisville KY, US
Nicholas Staten - Kirkwood MO, US
International Classification:
G01N 33/564
Abstract:
Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided.

Detecting Complement Activation

View page
US Patent:
20150056639, Feb 26, 2015
Filed:
Sep 12, 2014
Appl. No.:
14/485150
Inventors:
- St. Louis MO, US
Don W. Moss - Louisville KY, US
Nicholas Staten - Kirkwood MO, US
International Classification:
G01N 33/53
US Classification:
435 792, 436501, 435 71
Abstract:
Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided.
Control profile
Don W Moss from Waltham, MA, age ~58 Get Report